Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

You may be eligible if

• Histologically confirmed endometrial adenocarcinoma
• * Advanced, recurrent, or persistent disease
• * Refractory to curative therapy
• HER2/neu gene amplification by fluorescent in situ hybridization
• Measurable disease
• * Previously irradiated field as sole site of measurable disease allowed if evidence of progression since completion of radiotherapy
• Performance status - GOG 0-2
• Absolute neutrophil count ? 1,500/mm\^3
• Platelet count ? 100,000/mm\^3
• Bilirubin ? 1.5 times upper limit of normal (ULN)
• Creatinine ? 1.5 times ULN
• LVEF ? 45% by echocardiogram or MUGA
• History of coronary artery disease and/or congestive heart failure allowed if medical management of condition has been stable within the past 6 months
• No active or unstable cardiac disease
• No active angina
• No myocardial infarction within the past 6 months
• No requirement for supplemental oxygen at rest or with ambulation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection requiring antibiotics
• No uncontrolled infection
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No other unstable medical condition that would preclude study participation
• At least 3 weeks since prior biologic and immunologic agents directed at the malignant tumor
• No prior anti-HER2 monoclonal antibody preparation
• No other concurrent immunotherapy
• Recovered from prior chemotherapy
• Multiple prior chemotherapy regimens allowed
• No more than 320 mg/m\^2 total dose of prior doxorubicin allowed (including doxorubicin HCl liposome or other liposomally encapsulated doxorubicin preparations)
• No concurrent chemotherapy
• At least 1 week since prior hormonal therapy directed at the malignant tumor
• No concurrent hormonal therapy
• * Continuation of hormone replacement therapy allowed
• See Disease Characteristics
• At least 3 weeks since prior radiotherapy for the malignant tumor and recovered
• No concurrent radiotherapy
• Recovered from prior recent surgery
• At least 3 weeks since any prior therapy directed at the malignant tumor
• No prior cancer treatment that would contraindicate study therapy